JP2024543497A5 - - Google Patents

Info

Publication number
JP2024543497A5
JP2024543497A5 JP2024528586A JP2024528586A JP2024543497A5 JP 2024543497 A5 JP2024543497 A5 JP 2024543497A5 JP 2024528586 A JP2024528586 A JP 2024528586A JP 2024528586 A JP2024528586 A JP 2024528586A JP 2024543497 A5 JP2024543497 A5 JP 2024543497A5
Authority
JP
Japan
Application number
JP2024528586A
Other languages
Japanese (ja)
Other versions
JP2024543497A (ja
JPWO2023083285A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/131290 external-priority patent/WO2023083285A1/en
Publication of JP2024543497A publication Critical patent/JP2024543497A/ja
Publication of JP2024543497A5 publication Critical patent/JP2024543497A5/ja
Publication of JPWO2023083285A5 publication Critical patent/JPWO2023083285A5/ja
Pending legal-status Critical Current

Links

JP2024528586A 2021-11-12 2022-11-11 ユビキチン特異的プロテアーゼ1(usp1)の小分子阻害剤及びその使用 Pending JP2024543497A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2021130284 2021-11-12
CNPCT/CN2021/130284 2021-11-12
CNPCT/CN2022/123821 2022-10-08
CN2022123821 2022-10-08
PCT/CN2022/131290 WO2023083285A1 (en) 2021-11-12 2022-11-11 Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof

Publications (3)

Publication Number Publication Date
JP2024543497A JP2024543497A (ja) 2024-11-21
JP2024543497A5 true JP2024543497A5 (https=) 2025-11-19
JPWO2023083285A5 JPWO2023083285A5 (https=) 2025-11-19

Family

ID=86335132

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024528586A Pending JP2024543497A (ja) 2021-11-12 2022-11-11 ユビキチン特異的プロテアーゼ1(usp1)の小分子阻害剤及びその使用

Country Status (17)

Country Link
US (1) US20250066348A1 (https=)
EP (1) EP4430049A4 (https=)
JP (1) JP2024543497A (https=)
KR (1) KR20240117555A (https=)
CN (1) CN119173515A (https=)
AU (1) AU2022387669A1 (https=)
CA (1) CA3235603A1 (https=)
CL (1) CL2024001398A1 (https=)
CO (1) CO2024006278A2 (https=)
CR (1) CR20240190A (https=)
DO (1) DOP2024000081A (https=)
GE (1) GEAP202416531A (https=)
IL (1) IL312640A (https=)
JO (1) JOP20240095A1 (https=)
MX (1) MX2024005756A (https=)
PE (1) PE20241350A1 (https=)
WO (1) WO2023083285A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20240191A (es) 2021-11-12 2024-09-13 Insilico Medicine Ip Ltd Inhibidores de molécula pequeña de proteasa 1 específica de ubiquitina (usp1) y usos de los mismos
US20250382289A1 (en) * 2022-02-18 2025-12-18 Xizang Haisco Pharmaceutical Co., Ltd. Pyrazolopyridine derivative and application thereof in medicine
WO2024022266A1 (en) * 2022-07-25 2024-02-01 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heteroaryl compounds as inhibitors of usp1
CN119522224A (zh) * 2022-08-09 2025-02-25 上海济煜医药科技有限公司 含氮杂环化合物作为泛素-特异性蛋白酶1抑制剂的制备方法、应用及其用途
IL319492A (en) * 2022-09-20 2025-05-01 Chia Tai Tianqing Pharmaceutical Group Co Ltd A carbonyl-fused heterocyclic derivative that acts as a ubiquitin-specific protease
CN120603835A (zh) * 2023-01-20 2025-09-05 杭州英创医药科技有限公司 作为usp1抑制剂的化合物
CN121511238A (zh) * 2023-07-05 2026-02-10 江苏亚虹医药科技股份有限公司 嘧啶类化合物、其制备方法及其医药用途
WO2025010245A1 (en) 2023-07-06 2025-01-09 Exelixis, Inc. Fused pyrazole derivatives as usp1 inhibitors
WO2025015905A1 (en) * 2023-07-14 2025-01-23 Laekna Therapeutics Shanghai Co., Ltd. Pyrimidine compounds and their use as usp1 inhibitors
TW202530200A (zh) * 2023-09-25 2025-08-01 大陸商上海濟煜醫藥科技有限公司 嗒𠯤酮類化合物作為泛素-特異性蛋白酶1抑制劑的製備方法、應用及其用途
TW202530229A (zh) * 2023-09-26 2025-08-01 大陸商上海濟煜醫藥科技有限公司 氮雜環胺類化合物作為泛素-特異性蛋白酶1抑制劑的製備方法、應用及其用途
WO2025102016A1 (en) 2023-11-10 2025-05-15 Vrise Therapeutics, Inc. Novel molecules as inhibitors of dna damage repair pathway
WO2025151705A1 (en) 2024-01-10 2025-07-17 Vrise Therapeutics, Inc. Novel inhibitors of dna damage repair pathway
WO2025227060A1 (en) * 2024-04-26 2025-10-30 Insilico Medicine Ip Limited Heterocyclic inhibitors of ubiquitin specific protease 1 (usp1) in combination with additional agents for use in the treatment of cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10189841B2 (en) * 2015-11-20 2019-01-29 Forma Therapeutics, Inc. Purinones as ubiquitin-specific protease 1 inhibitors
BR112021010715A2 (pt) * 2018-12-20 2021-11-16 Ksq Therapeutics Inc Pirazolopirimidinas substituídas e purinas substituídas e seu uso como inibidores de protease de processamento ubiquitina-específica 1 (usp1)
CA3168009A1 (en) * 2020-02-14 2021-08-19 KSQ Therapeutics, Inc. Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (usp1) inhibitors and poly (adp-ribose) polymerase (parp) inhibitors
KR20230098186A (ko) * 2020-10-30 2023-07-03 케이에스큐 세러퓨틱스 인코포레이티드 치환된 피라졸로피리미딘의 고체 상태 형태 및 이의 용도
US20240182481A1 (en) * 2021-02-15 2024-06-06 Tango Therapeutics, Inc. Pyrrolo[3,2-d]pyrimidine compounds and methods of use in the treatment of cancer
AU2022238886A1 (en) * 2021-03-17 2023-09-14 Medivir Ab Purine derivatives as anticancer agents
WO2022199652A1 (en) * 2021-03-24 2022-09-29 Impact Therapeutics (Shanghai) , Inc Five-membered heteroaryl-pyrimidine compounds as usp1 inhibitors and the use thereof
MX2023011709A (es) * 2021-04-07 2023-10-12 Forma Therapeutics Inc Inhibidor de la proteasa 1 especifica de ubiquitina (usp1).

Similar Documents

Publication Publication Date Title
JP2024543497A5 (https=)
BR102022025291A2 (https=)
BR102023014872A2 (https=)
BR102023012440A2 (https=)
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR102023008688A2 (https=)
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR102022026909A2 (https=)
BR102022023461A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
CN307045229S (https=)
CN307047066S (https=)
CN307044823S (https=)
BY13157U (https=)
BY23965C1 (https=)
BY13158U (https=)
BY13153U (https=)
CN307044910S (https=)